Special features of interferonlambda contents in blood serum of the patients with HIV infection

Cover Page

Cite item


Studies in HIV infection remain an important issue for modern medicine, which, becomes controlled due to widespread usage of antiretroviral therapy. At the same time, however, it cannot be cured completely, and there is a number of “white spots” in understanding immunopathogenesis of disorders complicating this disease. The in-depth studies of interferon system, in particular from the lambda family, are desirable, because of their antiviral activity in HIV-infected patients. The aim of our study was to evaluate the content of interferons-lambda: IFNλ1 (IL-29) and IFNλ3 (IL-28B) in patients with HIV infection.
Blood serum of 120 patients with HIV infection (average age 49.7±6.2 years) who were treated in the outpatient setting at the Center for AIDS Prevention and Control of Regional Clinical Hospital No. 2 in Vladivostok was subjected to laboratory testing. HIV infection 4A was the main clinical diagnosis in all the patients, i.e., the stage of secondary diseases, remission phase on the background of antiretroviral therapy (ARVT). In 52 patients, chronic viral hepatitis C was found as a concomitant disease. The content of IFNλ1 (IL-29) and IFNλ3 (IL-28B) in venous blood serum was determined by ELISA technique using a “Multiscan” analyzer. The ELISA reagents were from R&D systems, catalog numbers DY5259; DY7246.
In the groups of patients with HIV infection, both with and without viral hepatitis C, the levels of IFNλ1 (IL-29) and IFNλ3 (IL-28B) were significantly reduced in comparison with control group. When comparing the IFN values between the groups, a more pronounced decrease in IFNλ1 (IL-29) was revealed among the patients with viral hepatitis C. When analyzing the level of IFNλ3 (IL-28B), an opposite pattern was observed, i.e., its values in the patients with HIV infection and viral hepatitis C were higher than in the group without hepatitis, but still did not reach appropriate values of the control group. Based on the data on IFNλ3 (IL-28B) antiviral effect upon HIV transmission via macrophages One may assume that induction and maintenance of higher type 3 interferon levels can favorably affect the course of HIV infection. The registered changes in IFNλ1 (IL-29) and IFNλ3 (IL-28B) levels in the patients with HIV and HCV suggest some viral effect upon innate immunity characterized by multidirectional changes, depending on presence or absence of hepatitis C virus. The studies of changes in innate immunity and role of type 3 interferons may extend our knowledge on the interaction between the human body and HIV, and will promote preventive measures and rehabilitation in the patients with HIV infection.

About the authors

S. V. Knysh

Pacific State Medical University

Author for correspondence.
Email: immunolog.vl@gmail.com
ORCID iD: 0000-0003-4571-1749

PhD (Medicine), Associate Professor, Department of Normal and Pathological Physiology

 690105, Russian Federation, Vladivostok, Russkaya str., 57к, apt 107

Phone: 7 (995) 773-65-23 

Russian Federation

L. F. Sklyar

Regional Clinical Hospital No. 2;
Pacific State Medical University

Email: lidiya.sklyar@hotmail.com

PhD, MD (Medicine), Professor, Deputy Head for Prevention and Control of AIDS and Infectious Diseases; Professor, Department of Infectious Diseases


E. V. Markelova

Pacific State Medical University

Email: markev2010@mail.ru

PhD, MD (Medicine), Professor, Head, Department of Normal and Pathological Physiology


A. S. Kuznetsov

Pacific State Medical University

Email: agent_zeborivch@mail.ru

 Postgraduate Student, Department of Normal and Pathological Physiology


N. P. Solovyeva

Regional Clinical Hospital No. 2

Email: patphis-vl@mail.ru

PhD (Medicine), Clinical Infectologist


M. A. Levenets

Pacific State Medical University

Email: maks_levenets22@mail.ru

Student, Military Training Center



  1. Малов С.И., Малов И.В., Колбасеева О.В., Степаненко Л.А., Дулгуун Б., Хабудаев В.А., Ющук Н.Д. Динамика синтеза интерферона-лямбда-1 у больных острым вирусным гепатитом С // Инфекционные болезни: новости, мнения, обучение, 2016. № 2. С. 78-83.
  2. Angel C.J.L., Pham E.A., Du H.,Vallania F., Fram B.J., Perez K., Nguyen T., Rosenberg-Hasson Y., Ahmed A., Dekker C.L., Grant P.M., Khatri P., Maecker H.T., Glenn J.S., Davis M.M., Furman D. Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination. Proc. Natl. Acad. Sci. USA, 2021, Vol. 118, no. 14, e2022928118. doi: 10.1073/pnas.2022928118.
  3. Bellanti F., Vendemiale G., Altomare E., Serviddio G. The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C. J. Immunol. Res., 2012, Vol. 2012, 849373. doi: 10.1155/2012/849373.
  4. Boisvert M., Shoukry N.H., Type III interferons in hepatitis C virus infection. Front. Immunol., 2016, Vol. 7, 628. doi: 10.3389/fimmu.2016.00628.
  5. Bruening J., Weigei B., Gerold G. The role of type III interferons in hepatitis C virus infection and therapy. J. Immunol. Res., 2017, Vol. 2017, 7232361. doi: 10.1155/2017/7232361.
  6. Casado C., Galvez C., Pernas M., Tarancon-Diez L., Rodriguez C., Sanchez-Merino V., Vera M., Olivares I., Pablo-Bernal R., Merino-Mansilla A., Romero J.D., Lorenzo-Redondo R., Ruiz-Mateos E., Salgado M., MartinezPicado J., Lopez-Galindez C. Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure. Sci. Rep., 2020, no. 10, 1902. doi: 10.1038/s41598-020-58696-y.
  7. Chaturvedi, N., Svarovskaia E.S., Mo H., Osinusi A.O., Brainard D.M., Subramanian G.M., McHutchinson J.G., Zeuzem S., Fellay J. Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes. eLife, 2019, Vol. 8, e42542. doi: 10.7554/eLife.42542.
  8. Friborg J., Ross-Macdonald P., Cao J., Willard R., Lin B., Eggers B., McPhee F. Impairment of type I but not type III IFN signaling by hepatitis C virus infection influences antiviral responses in primary human hepatocytes. PLoS One, 2015, Vol. 10, no. 3, 0121734. doi: 10.1371/journal.pone.0121734.
  9. Goel R.R., Kotenko S.V., Kaplan M.J. Interferon lambda in inflammation and autoimmune rheumatic diseases. Nat. Rev. Rheumatol., 2021, Vol. 17, no. 6, pp. 349-362.
  10. Liu M., Zhou D., Wang X., Zhou W., Ye L., Li J., Wang Y., Ho W. IFN-λ3 Inhibits HIV infection of macrophages through the JAK-STAT Pathway. PLoS One, 2012, Vol. 7, no. 4, e35902. doi: 10.1371/journal.pone.0035902.
  11. Syedbasha M., Egli A. Interferon lambda: modulating immunity in infectious diseases. Front. Immuno., 2017, Vol. 8, 119. doi: 10.3389/fimmu.2017.00119.

Supplementary files

There are no supplementary files to display.

Copyright (c) 2021 Knysh S.V., Sklyar L.F., Markelova E.V., Kuznetsov A.S., Solovyeva N.P., Levenets M.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies